Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells
about
Involvement of Kallikrein-Related Peptidases in Normal and Pathologic ProcessesEvidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cellsMastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond networkDirect and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics.Evolutionary history of tissue kallikreinsThe effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention.Genetic association of the KLK4 locus with risk of prostate cancer.The role of epithelial plasticity in prostate cancer dissemination and treatment resistanceUpregulation of SATB1 is associated with prostate cancer aggressiveness and disease progressionEnzymatically active prostate-specific antigen promotes growth of human prostate cancers.Male reproductive cancers and infertility: a mutual relationship.Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro studyClinical significance of kallikrein-related peptidase-4 in oral cancerIntegrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer modelsHepatocyte growth factor increases the invasive potential of PC-3 human prostate cancer cells via an ERK/MAPK and Zeb-1 signaling pathway.The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).Development of peptides specifically modulating the activity of KLK2 and KLK3.New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.Functional roles of human kallikrein-related peptidases.Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Targeting kallikrein-related peptidases in prostate cancer.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma.Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cellsKLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/β-catenin signaling pathway.Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical ApplicationSecretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug.Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells.
P2860
Q26771266-2A8A850F-1CBF-4E6E-9870-03DE36552B0DQ28241633-34ECC282-EEA2-4FFC-93E0-72D1DE06133DQ28740672-5611DC1C-60A3-4623-BC9A-AD897C4DAD2DQ30825171-A83BDBF4-5032-48A0-8880-343E0D194B45Q33745045-8060F031-EBEA-4491-8CEC-62B65688B15DQ34187693-67FB2412-F3D7-488B-A9C0-DE568A9244F8Q34284428-219E286C-64EC-45D4-B18E-A7C2F1D0B1D6Q34412503-3F05D13E-B7D9-49F1-BD02-0DC1BBB6EBC0Q34505037-BC4330FA-07B7-41EA-88CA-4A0333B45D33Q34545163-05DBB8E1-BA48-4820-A448-7D887ABA9D94Q35048230-2E850FB6-AB14-475B-A5AC-BA30E5F0A8EEQ35585478-5A28B0DD-3D9E-4070-8CC4-0AA171B6D857Q35637218-2D55DF08-1E42-4B7A-BF77-D350E519FAE2Q36079284-66E71564-E0F3-461F-A291-BA6575AECD3DQ36435777-6775EB72-675B-4B12-A7E4-CEF5D8BF6FE8Q36502905-042B5311-9EE6-4CE5-9E8C-58E0EC65F4FDQ36519383-6A0C0A98-628F-4934-9A9A-2DA8223FCEABQ36857803-EB414742-CC90-4752-919D-F8813C86AB39Q37010879-C6B19160-1700-41B6-A7C2-371D7BBC6F40Q37216570-DC48B7E0-9984-4D12-B1D9-5172133D3F07Q37216674-E61031E7-1357-408E-8A29-F800ACD2786DQ37453804-D13A89E3-8B9B-4BF1-8C07-0FF965DF30BFQ37612613-63A00E31-8579-49EB-A0DC-E8B9072A7E60Q37690308-B23089D4-77D0-4712-8A66-0DE80EA1E37BQ37728684-E832FC92-0D5A-47D2-90AD-B62864BA1EE2Q38184632-54087654-84B5-421B-BB52-EAFE75A11E66Q38191293-44D33A08-EA6C-4B9E-9D76-E4D6797D46E0Q38362486-11D56D84-ABC7-463A-B884-D1E5FC7B7331Q38413737-E8A97A33-2DB6-492E-B117-4B32C0018B31Q38415467-44EAF932-0B40-40BE-8537-BDEFA62878DBQ38703356-294914D2-62E2-4EFB-8BD9-64A2E0F6BD6FQ38718409-C097E09F-395A-491A-819B-7EA3AFF53F7BQ38737293-1CC45D14-FB9F-4D67-A017-A8C798011B71Q38760061-2774A5EF-1865-4859-88F0-C24FB4682C41Q38967490-26C082E9-4C41-4A7B-BADC-61DE2C5A6043Q39080408-AF9256F0-7CF8-47A0-BA37-2C7307966CFAQ39493165-B6984545-5901-492A-A0D0-E15EB05E20A6Q39552861-EFC36C1D-072B-4BA7-A26F-29BFE09704E1Q39592007-79FC68CA-EFF2-4B40-94E3-386DCFEE9DEBQ39735812-D5B76894-3CE6-49AD-AB73-72216CDA17A9
P2860
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@ast
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@en
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@nl
type
label
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@ast
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@en
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@nl
prefLabel
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@ast
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@en
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@nl
P2093
P3181
P356
P1476
Kallikrein 4 (hK4) and prostat ...... ffect in prostate cancer cells
@en
P2093
A C Herington
J A Clements
M G Lawrence
R L Collard
T L Veveris-Lowe
P304
P3181
P356
10.1677/ERC.1.00958
P407
P577
2005-09-01T00:00:00Z